Beta Drugs Reports Strong Q1FY27 Results Driven by Oncology Growth and Efficient Operations

Beta Drugs Reports Strong Q1FY27 Results Driven by Oncology Growth and Efficient Operations​

Beta Drugs Limited has reported robust consolidated financial results for the first quarter of fiscal year 2027 (Q1FY27), demonstrating significant growth across its key business segments. The company recorded total sales of Rs 125.55 crores, marking a substantial 25.3% increase from the Rs 100.2 crores reported in the previous fiscal year. Total revenues reached Rs 127.13 crores.

The quarterly performance was underpinned by stellar growth in branded oncology and CMO (Contract Manufacturing Organization) services. The branded oncology business delivered a 47% year-on-year growth, contributing sales of INR 33.0 Crores. The CMO segment also showed robust growth at 41% year-on-year, bolstered by strong client traction and the introduction of proprietary NDDS products within the CMO space. Looking ahead, Beta Drugs anticipates even better performance in FY27 for this business segment due to increased realisations associated with platins.

Beta Drugs’ exports division generated INR 17.2 Crores in Q1FY27. Management noted that the exports business is poised for accelerated growth throughout the remainder of FY27 as order momentum starts picking up across markets. Furthermore, the Nivian segment achieved a 45% year-on-year growth, driven by increased market penetration and the performance of new products launched during Q4 of FY26.

Margin Improvement and Profitability​

The company saw significant improvements in operational efficiency and profitability. Consolidated EBITDA stood at Rs 28.95 crores (including other income) and Rs 27.37 Crores (excluding other income). This represents a consolidated EBITDA growth of 38.9% year-on-year, with EBITDA margins standing at 23.06% (including other income) and 21.80% (excluding other income) in Q1FY27.

A key driver for improved margins was the increase in Gross Margins, which rose to 56.6% in Q1FY27 from 50.4% in Q1FY26. This margin enhancement is attributed to a favorable shift in the sales mix towards branded businesses and Nivian products. Management expects this trend toward improved EBITDA margins to continue as the business profile shifts favourably.

On the net profit front, Beta Drugs recorded a net profit of INR 16.5 Crores, corresponding to a net margin of 13.1%. This represents a substantial 40.92% growth compared to the INR 11.7 Crores reported in Q1FY26. The increase in Net Profit was primarily achieved through reduced finance costs related to CCDs issued in November 2024 and converted in May 2026. Interest cost associated with these CCDs for Q1FY27 stood at INR 0.75 Crores, down from INR 2.1 Crores in Q1FY26.

Outlook and Strategic Vision​

Beta Drugs is committed to its long-term vision of becoming a leading formulations company by 2030. This vision targets accelerated growth and higher margins, aiming for high margin businesses—including proprietary branded products and exports—to contribute over 80% of the total turnover by 2030. The company continues to assert its position as one of the fastest-growing players in the Indian branded oncology pharmaceutical market, coupled with a strong focus on innovation.

The ongoing investment in Research and Development (R&D) has resulted in differentiated products, such as NDDS, and solidified its presence both domestically and internationally. For FY27, Beta Drugs is on track to deliver 20-25% growth on a consolidated basis. The backward integration of the company into Key Starting Materials (KSMs) and advanced intermediates is expected to further enhance operating margins through the shifting product mix toward branded business. The R&D pipeline includes several NDDS products targeted for launch in FY27 and FY28, complementing its efforts to be a First or Few to Launch in India.

This performance helps Beta Drugs meet the growing global demand for effective cancer treatments as the oncology market continues to expand both domestically and internationally.

BETA Stock Price Movement​

As of 9:02 AM during the pre-open session, shares of BETA DRUGS LIMITED are slipping sharply by 20.00%, with the equity trading at ₹1783.3. This substantial drop reflects a loss of ₹445.80 from its previous close of ₹2229.1.